Andreas Engert

TL;DR: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy.

TL;DR: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.

TL;DR: Elderly patients with Hodgkin's lymphoma have a poorer risk profile compared with younger HL patients and experience more severe treatment-associated toxicity, the major factors explaining the poorer overall outcome of elderly HL patients.

TL;DR: There are no differences in survival between these regimens in elderly patients with newly diagnosed HD and Hodgkin-specific FFTF at 5 years was 55% after COPP-ABVD and 74% after BEACOPP (P=0.13).

TL;DR: In patients age ≥ 60 years with HL, four cycles of ABVD is associated with substantial dose reduction, treatment delay, toxicity, and treatment-related mortality.